Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Payables: 2013-2025

Historic Payables for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $45.2 million.

  • Fortress Biotech's Payables fell 29.97% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.5 million, marking a year-over-year decrease of 20.41%. This contributed to the annual value of $65.5 million for FY2024, which is 10.96% down from last year.
  • As of Q3 2025, Fortress Biotech's Payables stood at $45.2 million, which was down 7.01% from $48.6 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Payables peaked at $108.4 million during Q1 2023, and registered a low of $44.6 million during Q1 2021.
  • Moreover, its 3-year median value for Payables was $68.9 million (2024), whereas its average is $72.5 million.
  • As far as peak fluctuations go, Fortress Biotech's Payables plummeted by 62.67% in 2021, and later surged by 104.44% in 2022.
  • Fortress Biotech's Payables (Quarterly) stood at $91.5 million in 2021, then grew by 9.75% to $100.4 million in 2022, then declined by 26.73% to $73.6 million in 2023, then declined by 10.96% to $65.5 million in 2024, then decreased by 29.97% to $45.2 million in 2025.
  • Its last three reported values are $45.2 million in Q3 2025, $48.6 million for Q2 2025, and $66.3 million during Q1 2025.